Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 1/20 | 0.33 |
| ▸ | GABRD | O14764 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.33 |
| ▸ | GABRE | P78334 | 1/20 | 0.33 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.33 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.33 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.33 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22874111 | 1.00 | GABRP (0.33) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL23912983 | 1.00 | GABRP (0.33) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL14244194 | 0.83 | GABRP (0.32) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL14244003 | 0.79 | GABRP (0.33) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL10321403 | 0.74 | GABRP (0.31) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL22883603 | 0.74 | — | — | |
| SCHEMBL23252586 | 0.74 | — | — | |
| SCHEMBL12913049 | 0.73 | — | — | |
| SCHEMBL29055275 | 0.72 | — | — | |
| SCHEMBL24157887 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2768067-B1 | Nonaqueous electrolytic solution and nonaqueous electrolyte secondary battery | MITSUBISHI CHEM CORP (JP) | 2017-09-06 | — | — | EP | claimed |
| EP-2768067-A2 | Nonaqueous electrolytic solution and nonaqueous electrolyte secondary battery | Mitsubishi Chemical Corporation (JP) | 2014-08-20 | — | — | EP | claimed |
| EP-2120279-B1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEM CORP (JP) | 2014-07-23 | — | — | EP | claimed |
| US-8697295-B2 | Nonaqueous electrolytic solution and nonaqueous electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2014-04-15 | — | — | US | claimed |
| US-20120231330-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-09-13 | — | — | US | claimed |
| US-20100035146-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2010-02-11 | — | — | US | claimed |
| EP-2120279-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | Mitsubishi Chemical Corporation (JP) | 2009-11-18 | — | — | EP | claimed |
| EP-3627609-B1 | ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, SECONDARY CELL, AND MODULE | DAIKIN IND LTD (JP) | 2024-02-28 | — | — | EP | disclosed |
| US-11916195-B2 | Electrolyte solution, electrochemical device, lithium ion secondary battery, and module | DAIKIN INDUSTRIES, LTD. (JP) | 2024-02-27 | — | — | US | disclosed |
| US-11916195-B2 | Electrolyte solution, electrochemical device, lithium ion secondary battery, and module | DAIKIN INDUSTRIES, LTD. (JP) | 2024-02-27 | — | — | US | disclosed |
| US-20230387465-A1 | COMPOUND, COMPOSITION, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY AND MODULE | DAIKIN INDUSTRIES, LTD. (JP) | 2023-11-30 | — | — | US | disclosed |
| US-20230387465-A1 | COMPOUND, COMPOSITION, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY AND MODULE | DAIKIN INDUSTRIES, LTD. (JP) | 2023-11-30 | — | — | US | disclosed |
| US-20230250046-A1 | FLUORINATED CARBOXYLIC ACID SALT COMPOUND | DAIKIN INDUSTRIES, LTD. (JP) | 2023-08-10 | — | — | US | disclosed |
| US-20090061325-A1 | ANODE, METHOD OF MANUFACTURING SAME, SECONDARY BATTERY, AND METHOD OF MANUFACTURING SAME | SONY CORPORATION (JP) | 2009-03-05 | — | — | US | disclosed |
| US-20090061325-A1 | ANODE, METHOD OF MANUFACTURING SAME, SECONDARY BATTERY, AND METHOD OF MANUFACTURING SAME | SONY CORPORATION (JP) | 2009-03-05 | — | — | US | disclosed |
| US-20080311472-A1 | ANODE AND METHOD OF MANUFACTURING THE SAME, AND BATTERY AND METHOD OF MANUFACTURING THE SAME | SONY CORPORATION (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080311472-A1 | ANODE AND METHOD OF MANUFACTURING THE SAME, AND BATTERY AND METHOD OF MANUFACTURING THE SAME | SONY CORPORATION (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080311472-A1 | ANODE AND METHOD OF MANUFACTURING THE SAME, AND BATTERY AND METHOD OF MANUFACTURING THE SAME | SONY CORPORATION (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080292971-A1 | ELECTROLYTIC SOLUTION AND BATTERY | SONY CORPORATION (JP) | 2008-11-27 | — | — | US | disclosed |
| EP-0714148-B1 | A lithium secondary battery | FURUKAWA BATTERY CO LTD (JP) | 2002-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250046-A1 | FLUORINATED CARBOXYLIC ACID SALT COMPOUND | NHERF1, SLC9A2, NPFFR2 | GABRP 2500/4885GABRD 4515/4885GABRA1 2246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.